Inflammation Is the Unifying Frame.
Endometriosis. Autoimmune disease. Accelerated post-menopausal cardiovascular risk. The female-skewed cognitive-decline curve. These are not four conditions. They are one mechanism expressed in four organ systems, treated by four specialties, billed as four ledgers.
The clinical evidence the frame rests on
Endometriosis is now firmly characterised in the specialty literature as a systemic inflammatory disease rather than a localised gynaecological condition. A 2025 npj Women's Health case-control study found that endometriosis patients carry approximately 2x the odds of at least one of ten distinct autoimmune diagnoses, including rheumatoid arthritis, Hashimoto's thyroiditis, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, pernicious anaemia, myositis, coeliac disease, inflammatory bowel disease, and psoriasis. A 2019 systematic review and meta-analysis (PMC6601386) produced consistent cross-condition effect sizes.
Effect sizes indicative, drawn from the 2019 PMC meta-analysis and the 2025 npj case-control study. The direction is consistent; the magnitude is consistent; the mechanism is Th2/Treg predominance and B-cell hyperactivation producing persistent systemic inflammation.
Shape derived from: post-menopausal CVD incidence (AHA 2024), lifetime osteoporotic-fracture risk (NOF 2023), preclinical-to-MCI progression (Alzheimer's Association Facts & Figures 2025), autoimmune flare windows (Ngo et al. 2014). Four independent curves, one shared onset window.
The mechanism, briefly
Three overlapping processes drive the shared inflammatory phenotype.
- X-chromosome inactivation escape. Between 15 and 23 percent of X-linked genes escape XCI silencing, producing biallelic expression of immune-critical genes (TLR7, TASL, CXCR3) in female immune cells. This yields both pandemic resilience and autoimmune susceptibility. Full mechanism in Biology as a Frontier.
- Fetal microchimerism. Fetal cells cross the placenta during every pregnancy and persist in maternal tissues for decades. Their graft-versus-host-like dynamics are a leading hypothesis for the mid-life concentration of female autoimmune onset.
- Estrogen as inflammation brake. Estrogen modulates inflammatory cytokine production. Its withdrawal at menopause removes the brake, producing the simultaneous acceleration of vascular inflammation, bone-remodelling inflammation (osteoporosis), and neuroinflammation (cognitive decline) across a single five-to-ten-year window.
What the current fiscal architecture does with this
The health system treats the four downstream expressions as independent problems in independent specialties. Endometriosis goes to gynaecology under the N80 code family. SLE goes to rheumatology under M32. Post-menopausal coronary disease goes to cardiology under I25. Alzheimer's goes to neurology under G30. Each specialty operates with its own clinical guidelines, its own trial evidence, its own therapeutic options, its own billing codes, and its own research grants.
The fragmentation has two direct consequences.
- Therapeutic duplication. A woman carrying endometriosis plus Hashimoto's plus early-onset hypertension sees three specialists who each prescribe within their own vertical. Anti-inflammatory interventions that might address the shared upstream are under-prescribed because no single specialty owns the upstream.
- Research under-combination. The R&D efficiency of a pharmaceutical pipeline that treats female chronic inflammation as a single therapeutic target (one trial, one regulatory path, four labelled indications) is much greater than the current architecture of four separate vertical programs. The commercial opportunity is documented; the organisational response has not caught up.
The reframe for three audiences
Pharmaceutical R&D. The Nrf2, IL-6, and TNF-alpha axes are already active drug-discovery territory for individual inflammatory diseases. A deliberate cross-indication strategy, pricing the endometriosis-plus-autoimmune-plus-postmenopausal-CVD population as a single commercial target, reduces per-indication trial cost and creates a label that matches the patient. See the coming pharma self-interest essay for the commercial mechanics.
Payers and health systems. A bundled-inflammation-care pathway at the primary-care level (a standing inflammation screen for women entering perimenopause, covering hs-CRP, hormone panel, endometrial-screen prompt, and autoimmune review of systems) is low cost and high capture. The downstream savings come from earlier intervention on conditions currently caught only at specialty referral.
Research funders. NIH Sex-as-Biological-Variable enforcement should include a specific requirement for cross-condition inflammatory comorbidity analysis in any pre-clinical or clinical work on any one of the four conditions above. The default expectation, today, treats the four as independent. Reversing that default costs nothing and surfaces the cross-indication signal at zero marginal investment.
Why this is an essay and not a guideline
The unifying frame is unlikely to be adopted by any single specialty society on its own, because specialty identity is built on the boundaries the frame collapses. It is more likely to move first at the payer and research-funder level, where the integrating institutional logic already exists. The purpose of this essay is to give that integrating logic a name, a set of citations, and a mapped set of downstream actions.
Related reading: Biology as a Frontier for the mechanistic biology; The Menopause Cascade for the post-menopausal compounding; The Architecture of Precision for the regulatory-policy layer.